Emcure Pharmaceuticals Limited has informed the Exchange about Transcript

Emcure Pharmaceuticals reported strong FY26 results crossing $1 billion in revenue at INR 9,204 crores, with 16.6% YoY growth exceeding guidance. The company achieved over 100 basis points improvement in base business EBITDA margins and 41% growth in adjusted PAT to INR 1,008 crores. Key partnerships with Novo Nordisk (Poviztra semaglutide), Sanofi (Amaryl & Cetapin), and Roche (nephrology products) are driving portfolio expansion. International markets grew 22.2% to INR 5,177 crores, with Europe growing 25.5%. The company completed Zuventus minority stake buyout and acquired Manx (UK) and Cutimed (Canada) portfolios. Q4 domestic growth was impacted by 5% due to Zuventus restructuring and attrition, though management confirms April performance is back on track. For FY27, management guides for low to mid-teen revenue growth with EBITDA margin expansion of 75-100 basis points.